Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may improve CV outcomes in patients with diabetes undergoing cancer therapy. The ...

Please provide your email address to receive an email when new articles are posted on . Older women who received early breast cancer treatment with anthracycline experienced fewer HF hospitalizations ...

There's nothing like the real world to shed light on the safety of new drugs and devices. Clinical trials may be the best way to compare treatments, but patients enrolled in trials are carefully ...

DURHAM, NC – The development of BMS-986094 (Bristol-Myers Squibb), a nucleotide-polymerase inhibitor for the treatment of chronic hepatitis C (HCV) infection, was terminated back in August 2012, but a ...

Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial We evaluated 2,808 echocardiograms in 829 breast cancer ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS. At the ASPC 2025 Congress ...

Harmful side effects from a common chemotherapy drug could be the result of a single mutation, according to a study published in Cell Stem Cell. The cardiotoxic effects of the chemotherapy drug ...

Fewer than half of all women with breast cancer treated with chemotherapy are followed up with the recommended cardiac monitoring to help identify left ventricular dysfunction, according to a new, ...

Doxorubicin (Doxo) is a widely used chemotherapeutic drug for cancer, though it can have toxic effects on the heart. A recent animal study investigated whether the cardioregulatory protein ...

Too much of anything is bad, goes the old adage. Sadly, that could be true of exercise as well. A new study has shown that high level of intense exercise could harm your heart. There is growing ...